Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Future Oncol. 2018 Jan 29;:

Authors: Cappuzzo F, Soo R, Hochmair M, Schuler M, Lam KC, Stehle G, Cseh A, Lorence RM, Linden S, Forman ND, Hilbe W, Jazieh AR, Tsai CM

Abstract
AIM: A global afatinib named patient use program in non-small-cell lung carcinoma (NSCLC) commenced in 2010.
MATERIALS & METHODS: Eligible NSCLC patients had progressed after clinical benefit on prior erlotinib/gefitinib and/or had activating EGFR/HER2 mutations, exhausted all other treatments, and were ineligible for afatinib trials.
RESULTS: Data, as of January 2016, were reported on 3966 heavily pretreated NSCLC patients (41 countries; 6 continents). Among 2595/3966 (65.4%) patients with tumor EGFR status, 2407 (92.8%) were EGFR mutation positive. Median time to treatment failure (2862/3966 [72.2%] patients with available data) was 4.4 months. Among 1141/2862 (39.9%) patients with response reported, objective response rate was 23.4% (267/1141). Safety findings were as expected.
CONCLUSION: Time to treatment failure durations and objective response rates were encouraging.

PMID: 29376400 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2EouTIb